Testicular Germ-Cell Tumours · Medical Oncology · First salvage · CDCT versus HDCT

Conventional-dose versus high-dose salvage chemotherapy

In relapsed metastatic GCT, how did conventional-dose salvage chemotherapy compare with high-dose chemotherapy (HDCT)?

International retrospective mixed-GCT comparison

Population

1,594 eligible

Study population as reported in the cited publication; cohort sizes and denominators are stated where available.

Evidence type

Mixed GCT · retrospective comparison

Not all evidence is randomized, comparative, or seminoma-specific.

Reported outcomes

In this retrospective international database, 2-year PFS was 50% with HDCT versus 28% with conventional-dose chemotherapy; 5-year OS was 53% versus 41%. Adjusted HRs favoured HDCT for PFS (0.44) and OS (0.65).

2-year PFS · HDCT

50%

2-year PFS · CDCT

28%

5-year OS · HDCT

53%

5-year OS · CDCT

41%

Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.

Interpretation and limitations

Non-randomized treatment allocation leaves residual confounding and selection bias. These results prompted a randomized comparison of TIP and TI-CE; they do not prove HDCT is superior for every patient or seminoma subgroup.

Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.

Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025

Primary study source

Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors. J Clin Oncol. 2011;29:2178–2184.

Original study / PubMed / registry ↗

Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.